WO2020150531A1 - Compositions à base de pétrolatum et méthodes de traitement de l'onychomycose - Google Patents

Compositions à base de pétrolatum et méthodes de traitement de l'onychomycose Download PDF

Info

Publication number
WO2020150531A1
WO2020150531A1 PCT/US2020/013959 US2020013959W WO2020150531A1 WO 2020150531 A1 WO2020150531 A1 WO 2020150531A1 US 2020013959 W US2020013959 W US 2020013959W WO 2020150531 A1 WO2020150531 A1 WO 2020150531A1
Authority
WO
WIPO (PCT)
Prior art keywords
petrolatum
onychomycosis
fungal
agent solution
based composition
Prior art date
Application number
PCT/US2020/013959
Other languages
English (en)
Inventor
Bradley BURNAM
Original Assignee
Global Health Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Health Solutions Llc filed Critical Global Health Solutions Llc
Priority to JP2021541460A priority Critical patent/JP2022522991A/ja
Priority to EP20741114.1A priority patent/EP3911337A4/fr
Priority to CA3127052A priority patent/CA3127052A1/fr
Publication of WO2020150531A1 publication Critical patent/WO2020150531A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • the present disclosure is broadly concerned with petrolatum-based compositions for the treatment and prevention of onychomycosis.
  • the disclosure is also concerned with methods for the treatment of onychomycosis using petrolatum-based compositions.
  • Onychomycosis also known as tinea unguium, is a highly prevalent fungal infection of the nail affecting 35 million people in the United States. Without treatment, onychomycosis may damage the nail unit and spread to other fingers or toes and skin. Onychomycosis affects 1 in 3 diabetics and increases the risk of secondary infections which may lead to foot disorders and limb amputations. Since, onychomycosis is generally a non-life threatening infection, it should ideally be treated topically. However, current topical treatments do not penetrate the nail plate rendering them ineffective due to an inability to reach microbes below the nail plate.
  • FIG. 1 depicts an electron microscope micrograph showing the structure of typical nails, according to an exemplary embodiment of the present disclosure.
  • FIG. 2 is a diagrammatic view depicting penetration of the presently disclosed topical compositions through the nail to deliver one or more anti-fungal agents to the site of infection below the nail, according to an exemplary embodiment of the present disclosure.
  • compositions and methods for the treatment of onychomycosis It has been unexpectedly discovered that the presently disclosed compositions comprising one or more anti-fungal agents dispersed as nanodroplets in a petrolatum carrier are effective in the treatment of onychomycosis. In particular, it has been unexpectedly discovered that the presently disclosed compositions are capable of penetrating the keratin surface and nail plate to deliver a pharmaceutically effective amount of anti-fungal agent directly to the site of infection. In particular, as depicted in FIG.
  • the presently disclosed compositions are capable of penetrating the keratin surface of the nail to carry active ingredients, such as anti-fungal agents, through the channels of the lipid bilayers and deliver the active ingredients to the nail bed and throughout the nail itself.
  • FIG. 1 depicts an electron micrograph of skin or nail comprising corneocytes interspaced by intercellular lipid bilayers.
  • water-based topical formulations cannot penetrate the corneocytes nor pass through the intercellular lipids interspersed between the corneocytes.
  • the presently disclosed petrolatum-based compositions are capable of passing through the intercellular lipid channels to penetrate the epidermal layer and enable deep delivery of antifungal ingredients, such as one or more anti fungal agents, to the site of the infection below the nail.
  • a method of treating onychomycosis in a subject may include applying a petrolatum-based composition to the nail of a subject in need of treatment.
  • the petrolatum-based composition may include a pharmaceutically effective amount of one or more anti-fungal agents in a petrolatum carrier.
  • the one or more anti-fungal agents is dispersed in the petrolatum carrier to form a stable petrolatum-based suspension.
  • the one or more anti-fungal agents is dispersed in the petrolatum carrier in the form of nanodroplets.
  • the nanodroplets may comprise, for example, one or more fungal agents and a polar solvent.
  • the one or more anti-fungal agents may be dissolved in a polar solvent to form an anti fungal agent solution and the anti-fungal agent solution dispersed in the petrolatum to form a stable suspension.
  • the one or more anti-fungal agents may include, for example, terbinafine HC1, ciclopirox, ciclopirox olamine, fluconazole, itraconazole, ketoconazole, amorolfine, efinaconazole, clotrimazole, miconazole (miconazole nitrate), and any combination thereof.
  • the onychomycosis may be distal subungual onychomycosis, or white superficial onychomycosis (WSO), or proximal subungual onychomycosis, or Candidal onychomycosis.
  • WSO white superficial onychomycosis
  • the onychomycosis may be caused by Trichophyton rubrum (T. rubrum ), or caused by Candida, or caused by Candida auris (C. auris).
  • the onychomycosis may be caused by multi-drug resistant C. auris.
  • the presently disclosed petrolatum-based composition may include, for example, greater than about 80% by weight petrolatum, or greater than about 90% by weight petrolatum, or greater than about 95% by weight petrolatum.
  • the petrolatum-based composition may include from about 0.05% to about 5% by weight of the one or more anti- fungal agents, or from about 0.05% to about 3% by weight of the one or more anti-fungal agents, or from about 0.1% to about 1% by weight of the one or more anti- fungal agents, or from about 0.2% to about 0.6% by weight of the one or more anti-fungal agents, or from about 0.3% to about 0.5% by weight of the one or more anti- fungal agents, or from about 0.1% to about 3.5% by weight of the one or more anti-fungal agents, or from about 0.05% to about 2.5% by weight of the one or more anti-fungal agents, or from about 0.5% to about 3% by weight of the one or more anti-fungal agents, or from about 0.5% to about 2.5% by weight of the one or
  • the petrolatum-based composition contains no emulsifier. In other instances, the petrolatum-based composition excludes an added emulsifier. As used herein, the term“added emulsifier” refers to an emulsifier in addition to the presently claimed components of the petrolatum-based composition. [0011] In at least some instances, the petrolatum-based composition may further include a cationic biocide selected from the group consisting of benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • the petrolatum-based composition may include from about 0.001% to about 0.15% by weight benzalkonium chloride (BZK), or from about 0.001% to about 0.01% by weight BZK, or from about 0.005% to about 0.007% by weight BZK.
  • BZK benzalkonium chloride
  • the presently disclosed petrolatum-based compositions may be prepared by a process that includes: (a) dissolving the one or more anti fungal agents in a polar solvent to give a anti- fungal agent solution; (b) heating the petrolatum to a temperature sufficient to cause the petrolatum to melt to give a melted petrolatum and heating the anti-fungal agent solution to a temperature higher than the temperature of the melted petrolatum to give a heated anti-fungal agent solution; (c) mixing the melted petrolatum and the heated anti-fungal agent solution to give a melted mixture; and (d) cooling the melted mixture to give the petrolatum-based composition.
  • the heated anti-fungal agent solution may have a temperature that is about 1°C to about 5°C higher than the temperature of the melted petrolatum.
  • the one or more anti-fungal agents are dissolved in a polar solvent to form an anti- fungal agent solution and the anti- fungal agent solution is dispersed in the petrolatum to form a stable suspension.
  • the petrolatum-based compositions may include from about 0.01% to about 5% by weight terbinafine HC1, or from about 0.01% to about 5% by weight ciclopirox, or from about 0.01% to about 5% by weight ciclopirox olamine, or from about 0.01% to about 5% by weight fluconazole, or from about 0.01% to about 5% by weight itraconazole, or from about 0.01% to about 5% by weight ketoconazole, or from about 0.01% to about 5% by weight amorolfine, or from about 0.01% to about 5% by weight efinaconazole, or from about 0.01% to about 5% by weight clotrimazole, or from about 0.01% to about 5% by weight miconazole (miconazole nitrate), or any combination thereof.
  • terbinafine HC1 or from about 0.01% to about 5% by weight ciclopirox, or from about 0.01% to about 5% by weight ciclopirox olamine, or from about
  • the petrolatum-based composition may be a petrolatum-based composition that includes petrolatum and a pharmaceutically effective amount of one or more anti-fungal agents.
  • the compositions may include, for example, greater than about 80% by weight petrolatum.
  • the compositions may also include a polar solvent.
  • the polar solvent may be water.
  • the one or more anti-fungal agents and the polar solvent may be dispersed in the petrolatum in the form of nanodroplets.
  • the petrolatum-based compositions contain no emulsifier.
  • the one or more anti fungal agents may be dissolved in a polar solvent to form an anti-fungal agent solution and the anti-fungal agent solution dispersed in the petrolatum.
  • the anti-fungal agent solution may be dispersed in the petrolatum to form a stable suspension such that the anti- fungal agent solution does not separate from the petrolatum for at least six months.
  • the resultant petrolatum-based compositions do not require an emulsifier to form a stable suspension of one or more anti-fungal agents dispersed in the petrolatum.
  • the petrolatum-based compositions prepared according to this process does not require high shear mixing to form a stable suspension of one or more anti-fungal agents in petrolatum in the absence of an added emulsifier.
  • the present disclosure provides for compositions that are petrolatum-based.
  • a petrolatum-based composition is made up primarily of petrolatum. The characteristics of a petrolatum-based composition differ from a composition containing only a small amount of petrolatum. In some embodiments, the petrolatum-based composition is greater than about 80% petrolatum.
  • the petrolatum-based composition is greater than about 81% petrolatum, greater than about 82% petrolatum, greater than about 83% petrolatum, greater than about 84% petrolatum, greater than about 85% petrolatum, greater than about 86% petrolatum, greater than about 87% petrolatum, greater than about 88% petrolatum, greater than about 89% petrolatum, greater than about 90% petrolatum, greater than about 91% petrolatum, greater than about 92% petrolatum, greater than about 93% petrolatum, greater than about 94% petrolatum, greater than about 95% petrolatum, greater than about 96% petrolatum, greater than about 97% petrolatum, greater than about 98% petrolatum, or greater than about 99% petrolatum.
  • the petrolatum is preferably medical grade petrolatum.
  • the composition also contains one or more anti-fungal agents dispersed throughout the petrolatum.
  • the one or more anti- fungal agents are the composition ingredient active in treating onychomycosis.
  • the presently disclosed compositions may also include cationic biocides, such as quaternary ammonium compounds, bisbiguanides, and polymeric biguanides.
  • compositions may include, but are not limited to, benzalkonium chloride, cetrimide, chlorhexidine, polihexanide biguanide (polihexanide, polyhexamethylene guanide, poly(iminoimidocarbonyl-iminoimidocarbonyl-iminohexamethylene),
  • compositions contain benzalkonium chloride (BZK) as a preservative.
  • BZK benzalkonium chloride
  • the total amount of cationic biocide in the composition generally constitutes less than about 1% by weight of the total composition. In preferred embodiments, the cationic biocide constitutes from about 0.1% to about 0.5% by weight, or more preferably, from about 0.1% to about 0.3% by weight to the total composition.
  • the remaining weight of the composition typically from about 0.1% to about 6% by weight of the petrolatum-based composition, is liquid. In some instsances, the composition contains about 5% water.
  • the one or more anti-fungal agents and cationic biocides that may be used in the presently disclosed compositions do not react with the petrolatum. Instead, the one or more anti-fungal agents and optional cationic biocides that may be included in the compositions are dispersed in the petrolatum as nanodroplets, and the petrolatum serves as a suspension matrix for the one or more anti-fungal agents and cationic biocides.
  • “Nanodroplet,” as used herein, is an aggregation of one or more anti-fungal agents and optionally any cationic biocide molecules in the petrolatum base.
  • Nanodroplets typically contain a small amount of water or other polar solvent in addition to the one or more anti-fungal agents and optional cationic biocides. Nanodroplets in accordance with the present disclosure may vary in size but generally the longest dimension of the nanodroplets measures from about 10 nm to about 10,000 nm.
  • the nanodroplets range from about 10 nm to about 100 nm, from about 100 nm to about 1000 nm, from about 1000 nm to about 2000 nm, from about 2000 nm to about 3000 nm, from about 3000 nm to about 4000 nm, from about 4000 nm to about 5000 nm, from about 5000 nm to about 6000 nm, from about 6000 nm to about 7000 nm, from about 7000 nm to about 8000 nm, from about 8000 nm to about 9000 nm, from about 9000 nm to about 10,000 nm.
  • the nanodroplets are dispersed through the petrolatum homogeneously.
  • an emulsifier is an added formulation ingredient used to reduce the tension between hydrophilic and hydrophobic surface ingredients, thereby facilitating the mixture hydrophilic and hydrophobic ingredients.
  • an emulsifier would be needed to disperse polar ingredients, such as a polar solvent, one or more anti-fungal agents, and cationic biocides, in a non-polar petrolatum suspension matrix.
  • the emulsifier may have a hydrophilic- lipophilic balance (HLB) of less than 10.
  • compositions described herein are stable.
  • stability refers to the integrity of the composition as a whole, and in particular, the stability of the nanodroplets in the petrolatum.
  • the petrolatum and the one or more anti- fungal agents and optional cationic biocides will not separate for greater than two years, meaning that the composition is shelf stable for at least two years.
  • Even under accelerated conditions, such as reduced pressure, the petrolatum and the one or more anti-fungal agents and optional cationic biocides do not separate, but rather the one or more anti-fungal agents and optional cationic biocides remain suspended as nanodroplets in the petrolatum.
  • compositions described herein also show exceptional chemical stability for the one or more anti-fungal agents and optional cationic biocides.
  • the chemical stability stems primarily from the low-temperature manufacturing process described below. The absence of excessive heat conditions in the manufacturing of the compositions improves the chemical stability (resistance to degradation) for the one or more anti-fungal agents and optional cationic biocides.
  • the petrolatum-based compositions described herein consist essentially of petrolatum, one or more anti-fungal agents, and water.
  • the petrolatum-based compositions consist essentially of petrolatum, one or more anti-fungal agents, benzalkonium chloride, and water.
  • the petrolatum-based compositions described herein consist of petrolatum, a cationic biocide, and one or more anti-fungal agents.
  • the petrolatum-based compositions described herein may further comprise a compound that stimulates healing. More specifically, the petrolatum-based compositions described herein may further comprise a compound that stimulates healing for use in intraoperative applications and chronic wound care applications.
  • Non-limiting examples of compounds that stimulate healing include polycaprolactone-tricalcium phosphate (PCL-TCP), collagen, chitosan, cellulose, thrombin, chondroitin sulfate (CS), chondroitin sulfate succinimidyl succinate (CS-NHS), and growth factors such as TGF-alpha, TGF-beta (TGFpi, TGFP2, TGFP3), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), fibroblast growth factor also referred to as keratinocyte growth factor (FGF1, FGF2, FGF4, FGF7), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), connective tissue growth factor (CTGF), activin, interleukin- 1 (ILla, IL1 b), TNFa, GM-CSF, or autologous intraoperative biologies such as platelet-rich plasma (PRP) and bone marrow (BM).
  • the petrolatum-based compositions described herein may further comprise a dermatologically acceptable carrier.
  • A“dermatologically-acceptable carrier,” as used herein, is a component or components suitable for use in contact with human keratinous tissue without undue toxicity, incompatibility, instability, allergic response, and the like. Where employed, the carrier is inert in the sense of not bringing about a deactivation of the active ingredients, and in the sense of not bringing about any adverse effect on the skin areas to which it is applied.
  • Common dermatological additives are also envisioned for some embodiments.
  • a dermatological additive is a whitening agent and/or hemostatic agent.
  • compositions may be incorporated in predetermined therapeutically effective amounts into disposables such as wipes, gauze, patches, wraps, bandages, adhesive strips, sponge, cotton swab, glove, sock, wrist bands, fabric, fibers, sutures, medication pad, underwear, tissue, pain-relief gel pack or bed liner and the like.
  • disposables such as wipes, gauze, patches, wraps, bandages, adhesive strips, sponge, cotton swab, glove, sock, wrist bands, fabric, fibers, sutures, medication pad, underwear, tissue, pain-relief gel pack or bed liner and the like.
  • the composition may be applied to the surface of, or impregnated into disposables.
  • the present disclosure also provides a method for making the compositions described in Section (I).
  • the process comprises: (a) dissolving one or more anti-fungal agents in a solvent to give an anti-fungal agent solution; (b) heating the petrolatum to a temperature sufficient to give a melted petrolatum, and heating the anti- fungal agent solution to a temperature higher than the temperature of the petrolatum to give a heated anti-fungal agent solution; (c) mixing the melted petrolatum and the heated anti-fungal agent solution to give a melted mixture; and, (d) cooling the melted mixture to give the petrolatum-based composition.
  • steps (a) - (d) are conducted sequentially.
  • the one or more anti-fungal agents as well the optional cationic biocide, selected from the group described in Section (I), is first dissolved in a solvent to give a anti- fungal agent solution.
  • Acceptable solvents for the anti-fungal agent solution include water or other solvents. Generally polar solvents are used.
  • the anti-fungal agents and optional cationic biocides are typically dissolved in the solvent a concentration ranging from about 0.05% to about 5%.
  • the amount of solvent used is from about 1:10 to about 1:30 the amount of petrolatum and more preferably is about 1:20 to the amount of petrolatum by volume.
  • the amount of one or more anti- fungal agents and optional cationic biocides can be calculated by one skilled in the art to provide the desired weight percentage for the final composition.
  • Both the anti-fungal agent solution and the petrolatum are heated.
  • the heating of these two ingredients can be conducted at the same time or sequentially so long as the melted petrolatum and the heated anti-fungal agent solution are at the appropriate temperatures during the mixing step.
  • Petrolatum is a solid that melts at approximately 37°C. As such, petrolatum may be heated to any temperature at or above 37°C.
  • the petrolatum may be heated to a temperature ranging from about 37°C to about 45°C, from about 40°C to about 50°C, from about 45°C to about 55°C, from about 50°C to about 60°C, from about 55°C to about 65°C, from about 60°C to about 70°C, from about 65°C to about 75°C, from about 70°C to about 80°C, from about 75°C to about 85°C, from about 80°C to about 90°C, from about 85°C to about 95°C, or from about 90°C to about 100°C or more. Higher temperatures may also be envisioned.
  • the petrolatum is heated to a temperature ranging from about 37°C to about 55°C, more preferably to a temperature ranging from about 40°C to about 50°C.
  • Heat may be provided to the petrolatum by any method known in the art, but a water bath or low temperature hot plate are preferred.
  • the anti-fungal agent solution is heated to a temperature above the temperature of the melted petrolatum. Any temperature above the temperature of the melted petrolatum may be used in a method of the present disclosure, provided that the heat does not cause excessive degradation of an active ingredient such as the one or more anti-fungal agents, or excessive evaporation of the active ingredient or polar solvent.
  • the anti-fungal agent solution may be heated to a temperature that is about 1°C to about 10°C, about 5°C to about 15°C, about 10°C to about 20°C, about 15°C to about 25°C, about 20°C to about 30°C, about 25°C to about 35°C, about 30°C to about 40°C, about 35°C to about 45°C, about 40°C to about 50°C, about 45°C to about 55°C, about 50°C to about 60°C or about 65°C or about 75°C higher than the temperature of the melted petrolatum. Higher temperatures may also be envisioned.
  • the anti- fungal agent solution is heated to a temperature that is about 1°C to about 10°C higher than the temperature of the melted petrolatum.
  • the anti-fungal agent solution is heated to a temperature that is about 1°C to about 5°C higher than the melted petrolatum.
  • the anti-fungal agent solution is heated to a temperature that is about 1°C, 2°C, 3°C, 4°C, or 5°C above the temperature of the melted petrolatum.
  • the heating can be provided by any means known in the art but is preferably provided by a water bath or low temperature hot plate.
  • the melted petrolatum and the heated anti-fungal agent solution are mixed to give a melted mixture containing petrolatum and the heated anti-fungal agent solution.
  • the mixing can be accomplished by a variety of methods including homogenization, acoustic mixing, and high RPM mixing. Depending on the batch size, the size of the mixer, and the type of mixing, the mixing may be conducted for several minutes or more.
  • the melted petrolatum and the heated anti-fungal agent solution fuse in the melted mixture.
  • the final composition After the melted petrolatum and the heated anti- fungal agent solution have fused they are allowed to cool and solidify into the composition described more fully in Section (I) (“the final composition”). Cooling may be achieved by reducing the amount of heat provided to the melted mixture, or cooling may be achieved passively under conditions where no heating is added. In some embodiments, cooling is controlled so that the temperature of the melting mixture is gradually lowered to ambient temperatures.
  • the product is preferably packaged a few degrees above its solidification point so that the packaging can be filled by pouring the melted mixture.
  • the composition preferably solidifies to the final composition in the package. The package is sealed after this solidification.
  • the process may be conducted with one or more anti-fungal agents, and optionally, one or more cationic biocides.
  • the anti-fungal agents and optionally the cationic biocides may be dissolved in s solvent separately or may be dissolved in the same solvent.
  • the addition of additional anti-fungal agents or optional cationic biocides does not change the process steps above.
  • the invention encompasses a method of preventing or treating onychomycosis in a subject using the compositions described herein.
  • compositions may be applied topically to the nail of a subject in need.
  • Subjects in need may be those having onychomycosis, including subjects having distal subungual onychomycosis, white superficial onychomycosis (WSO), proximal subungual onychomycosis, and Candidal onychomycosis.
  • the onychomycosis may be caused by, for example, Trichophyton rubrum (T. rubrum ) or Candida auris ( C . auris), including multi-drug resistant C. auris.
  • the subject is preferably human but the composition may also be useful in animals, particularly mammals, for example domestic animals, livestock, or other types of animals.
  • the composition is applied to the nail of the subject.
  • Application to the nail includes application to a site having onychomycosis as well as to sites that may be susceptible to acquiring onychomycosis. Therefore, the presently disclosed compositions may be applied to skin or nails in order to prevent infection by the causative agent responsible for onychomycosis.
  • the presently disclosed compositions may also be used as a topical dressing to a nail and/or skin of a subject in order to prevent or reduce the occurrence of onychomycosis.
  • the terms“applied to the nail” or“applying to the nail,” in all their forms, as used throughout this disclosure in reference to applying the presently disclosed compositions to the nail of a subject refers to all modes of administration of the compositions to the nail and/or nearby skin of a patient including topical administration of the compositions directly to the nail or surrounding skin of a subject or causing contact between the compositions and the nail of a subject through, for instance, a wrap, gauze, or bandage impregnated or containing the presently disclosed compositions.
  • the amount of composition applied in the methods described herein can and will vary depending on the condition being treated and the severity of that condition. Generally, the amount used is sufficient to cover the affected nail area with a thin layer of the composition.
  • the composition is applied directly to the nail. In some embodiments, the composition is spread so that it forms a thin layer over the treatment area. In other embodiments, the composition is spread by a melting action that occurs as the warmth of the patient’s nail and surrounding skin melts the petrolatum or pharmaceutically acceptable carrier.
  • the composition may be covered with a bandage after application.
  • the compositions may also be impregnated into a bandage or other material that is applied to the treatment area.
  • compositions when applied to the nail and surrounding skin are non-irritating and non-cytotoxic. These properties allow the composition to be used on sensitive treatment areas. These characteristics also allow for use to treat or prevent onychomycosis over a long period, such as for example 2 weeks, 4 weeks, 6 weeks, 8 weeks, or longer without irritation to the treated area. It will be recognized however, that the compositions may be used for shorter periods of time if necessary.
  • compositions are also capable of extended release of the one or more anti fungal agents and optionally cationic biocides to the area of application.
  • extended release as used herein means that the compositions release anti-fungal agents and optionally cationic biocides to the application site over a period of time extending past twelve hours. The time over which the extended release is provided is variable depending on the amount of the composition that is applied, but in general, the release of anti-fungal agents and optional cationic biocides is extended beyond the initial application and anti-fungal agents and optional cationic biocides has been shown to be released for up to 1 week. This extended release allows the composition to be applied less frequently and improves patient compliance with the treatment.
  • compositions of the present disclosure also offer kinetic release when applied to the skin or nails.
  • Kinetic release means that the anti-fungal agents and optional cationic biocides are released to the treatment area more rapidly when the treatment area is hotter.
  • Formulation 1 is prepared by adding 2540.3 pounds of white petrolatum to a tank that has been cleaned and sterilized.
  • the petrolatum in the tanks is heated to 110°C to 113°F in order to cause the petrolatum to melt.
  • 133.70 pounds of water is mixed with Terbinafine HC1 and BZK to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to 122°F. With the melted petrolatum at a temperature from about 110°F to about 113°F and the anti-fungal agent solution at a temperature of 122°F, the anti-fungal agent solution is slowly added to the petrolatum while mixing.
  • the heat is decreased slowly to from about 96°F to about 104°F.
  • the resulting formulation contains the following ingredients by weight percent: 95% petrolatum, 0.2% Terbinafine HC1, 0.13% BZK, and 4.67% water.
  • the formulation is observed to be stable for at least 6 months. During the 6 month observation period, the anti-fungal solution remains substantially suspended in the petrolatum carrier thereby resulting in a composition suitable for therapeutic use for the treatment of onychomycosis by topical administration to the nail and surrounding skin of a subject in need thereof.
  • Formulation 2 is prepared in accordance with the present disclosure by mixing Terbinafine HC1 and water to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to a temperature from about 1°C to about 5°C higher than the temperature of the melted petrolatum and mixed.
  • a stable petrolatum-based Terbinafine HC1 composition is formed, which comprises from about 0.01% to about 5% by weight terbinafine HC1 and greater than 85% petrolatum.
  • one or more cationic biocides is added to the anti-fungal agent solution prior to mixing with the melted petrolatum such that the resultant stable petrolatum-based composition further includes from about 0.001% to about 0.15% cationic biocide.
  • cationic biocides may include, for example, benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • Formulations 1 and 2 (petrolatum- based compositions comprising Terbinafine HC1)
  • topical administration of Formulations 1 and 2 in the treatment of human subjects having onychomycosis will be studied using a randomized, double-blind clinical study.
  • a group of human subjects will be topically administered the compositions corresponding to Formulations 1 and 2 of Examples 1 and 2.
  • the petrolatum-based compositions comprising Terbinafine HC1 will be applied to the nail of a subject having or otherwise affected by onychomycosis. Subjects receiving such treatment will have improved standard clinical outcomes.
  • subjects receiving treatment according to the presently disclosed methods and techniques are will exhibit a reduced rate of occurrence of onychomycosis in the nails or portions thereof receiving treatment as well as reduced clinical signs of onychomycosis.
  • Similar improved standard clinical outcomes will be obtained for subjects having onychomycosis caused by T. rubrum, Candida, as well as for the distal subungual onychomycosis, white superficial onychomycosis (WSO), proximal subungual onychomycosis, and Candidal onychomycosis sub-types of onychomycosis.
  • Formulation 3 is prepared by adding 2540.3 pounds of white petrolatum to a tank that has been cleaned and sterilized.
  • the petrolatum in the tanks is heated to 110°C to 113°F in order to cause the petrolatum to melt.
  • 133.70 pounds of water is mixed with Ciclopirox and BZK to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to 122°F. With the melted petrolatum at a temperature from about 110°F to about 113°F and the anti-fungal agent solution at a temperature of 122°F, the anti-fungal agent solution is slowly added to the petrolatum while mixing.
  • the heat is decreased slowly to from about 96°F to about 104°F.
  • the resulting formulation contains the following ingredients by weight percent: 95% petrolatum, 0.2% Ciclopirox, 0.13% BZK, and 4.67% water.
  • the formulation is observed to be stable for at least 6 months. During the 6 month observation period, the anti-fungal solution remains substantially suspended in the petrolatum carrier thereby resulting in a composition suitable for therapeutic use for the treatment of onychomycosis by topical administration to the nail and surrounding skin of a subject in need thereof.
  • Formulation 4 is prepared in accordance with the present disclosure by mixing Ciclopirox and water to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to a temperature from about 1°C to about 5°C higher than the temperature of the melted petrolatum and mixed.
  • a stable petrolatum-based Ciclopirox composition is formed, which comprises from about 0.01% to about 5% by weight Ciclopirox and greater than 85% petrolatum.
  • one or more cationic biocides is added to the anti-fungal agent solution prior to mixing with the melted petrolatum such that the resultant stable petrolatum-based composition further includes from about 0.001% to about 0.15% cationic biocide.
  • Such cationic biocides may include, for example, benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • Formulations 3 and 4 (petrolatum- based compositions comprising Ciclopirox) in the treatment of human subjects having onychomycosis will be studied using a randomized, double-blind clinical study.
  • a group of human subjects will be topically administered the compositions corresponding to Formulations 3 and 4 of Examples 4 and 5.
  • the petrolatum-based compositions comprising Ciclopirox will be applied to the nail of a subject having or otherwise affected by onychomycosis. Subjects receiving such treatment will have improved standard clinical outcomes.
  • subjects receiving treatment according to the presently disclosed methods and techniques are will exhibit a reduced rate of occurrence of onychomycosis in the nails or portions thereof receiving treatment as well as reduced clinical signs of onychomycosis. Similar improved standard clinical outcomes will be obtained for subjects having onychomycosis caused by T. rubrum, Candida, as well as for the distal subungual onychomycosis, white superficial onychomycosis (WSO), proximal subungual onychomycosis, and Candidal onychomycosis sub-types of onychomycosis.
  • Example 7 Exemplary Formulation Process: Petrolatum-Based Ciclopirox Olamine Composition
  • Formulation 5 is prepared by adding 2540.3 pounds of white petrolatum to a tank that has been cleaned and sterilized.
  • the petrolatum in the tanks is heated to 110°C to 113°F in order to cause the petrolatum to melt.
  • 133.70 pounds of water is mixed with Ciclopirox Olamine and BZK to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to 122°F. With the melted petrolatum at a temperature from about 110°F to about 113°F and the anti-fungal agent solution at a temperature of 122°F, the anti-fungal agent solution is slowly added to the petrolatum while mixing.
  • the heat is decreased slowly to from about 96°F to about 104°F.
  • the resulting formulation contains the following ingredients by weight percent: 95% petrolatum, 0.2% Ciclopirox Olamine, 0.13% BZK, and 4.67% water.
  • the formulation is observed to be stable for at least 6 months. During the 6 month observation period, the anti-fungal solution remains substantially suspended in the petrolatum carrier thereby resulting in a composition suitable for therapeutic use for the treatment of onychomycosis by topical administration to the nail and surrounding skin of a subject in need thereof.
  • Formulation 6 is prepared in accordance with the present disclosure by mixing Ciclopirox Olamine and water to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to a temperature from about 1°C to about 5°C higher than the temperature of the melted petrolatum and mixed.
  • a stable petrolatum-based Ciclopirox Olamine composition is formed, which comprises from about 0.01% to about 5% by weight Ciclopirox Olamine and greater than 85% petrolatum.
  • one or more cationic biocides is added to the anti-fungal agent solution prior to mixing with the melted petrolatum such that the resultant stable petrolatum-based composition further includes from about 0.001% to about 0.15% cationic biocide.
  • cationic biocides may include, for example, benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • Formulations 5 and 6 (petrolatum- based compositions comprising Ciclopirox Olamine) in the treatment of human subjects having onychomycosis will be studied using a randomized, double-blind clinical study.
  • a group of human subjects will be topically administered the compositions corresponding to Formulations 5 and 6 of Examples 7 and 8.
  • the petrolatum-based compositions comprising Ciclopirox Olamine will be applied to the nail of a subject having or otherwise affected by onychomycosis. Subjects receiving such treatment will have improved standard clinical outcomes.
  • subjects receiving treatment according to the presently disclosed methods and techniques are will exhibit a reduced rate of occurrence of onychomycosis in the nails or portions thereof receiving treatment as well as reduced clinical signs of onychomycosis.
  • Similar improved standard clinical outcomes will be obtained for subjects having onychomycosis caused by T. rubrum, Candida, as well as for the distal subungual onychomycosis, white superficial onychomycosis (WSO), proximal subungual onychomycosis, and Candidal onychomycosis sub-types of onychomycosis.
  • Formulation 7 is prepared by adding 2540.3 pounds of white petrolatum to a tank that has been cleaned and sterilized.
  • the petrolatum in the tanks is heated to 110°C to 113°F in order to cause the petrolatum to melt.
  • 133.70 pounds of water is mixed with Fluconazole and BZK to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to 122°F. With the melted petrolatum at a temperature from about 110°F to about 113°F and the anti-fungal agent solution at a temperature of 122°F, the anti-fungal agent solution is slowly added to the petrolatum while mixing.
  • the heat is decreased slowly to from about 96°F to about 104°F.
  • the resulting formulation contains the following ingredients by weight percent: 95% petrolatum, 0.2% Fluconazole, 0.13% BZK, and 4.67% water.
  • the formulation is observed to be stable for at least 6 months. During the 6 month observation period, the anti-fungal solution remains substantially suspended in the petrolatum carrier thereby resulting in a composition suitable for therapeutic use for the treatment of onychomycosis by topical administration to the nail and surrounding skin of a subject in need thereof.
  • Formulation 8 is prepared in accordance with the present disclosure by mixing Fluconazole and water to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to a temperature from about 1°C to about 5°C higher than the temperature of the melted petrolatum and mixed.
  • a stable petrolatum-based Fluconazole composition is formed, which comprises from about 0.01% to about 5% by weight Fluconazole and greater than 85% petrolatum.
  • one or more cationic biocides is added to the anti-fungal agent solution prior to mixing with the melted petrolatum such that the resultant stable petrolatum-based composition further includes from about 0.001% to about 0.15% cationic biocide.
  • Such cationic biocides may include, for example, benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • Formulations 7 and 8 (petrolatum- based compositions comprising Fluconazole) in the treatment of human subjects having onychomycosis will be studied using a randomized, double-blind clinical study.
  • a group of human subjects will be topically administered the compositions corresponding to Formulations 7 and 8 of Examples 10 and 11.
  • the petrolatum- based compositions comprising Fluconazole will be applied to the nail of a subject having or otherwise affected by onychomycosis. Subjects receiving such treatment will have improved standard clinical outcomes.
  • subjects receiving treatment according to the presently disclosed methods and techniques are will exhibit a reduced rate of occurrence of onychomycosis in the nails or portions thereof receiving treatment as well as reduced clinical signs of onychomycosis. Similar improved standard clinical outcomes will be obtained for subjects having onychomycosis caused by T. rubrum, Candida, as well as for the distal subungual onychomycosis, white superficial onychomycosis (WSO), proximal subungual onychomycosis, and Candidal onychomycosis sub-types of onychomycosis.
  • Example 13 Exemplary Formulation Process: Petrolatum-Based Itraconazole Composition
  • Formulation 9 is prepared by adding 2540.3 pounds of white petrolatum to a tank that has been cleaned and sterilized.
  • the petrolatum in the tanks is heated to 110°C to 113°F in order to cause the petrolatum to melt.
  • 133.70 pounds of water is mixed with Itraconazole and BZK to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to 122°F. With the melted petrolatum at a temperature from about 110°F to about 113°F and the anti-fungal agent solution at a temperature of 122°F, the anti-fungal agent solution is slowly added to the petrolatum while mixing.
  • the heat is decreased slowly to from about 96°F to about 104°F.
  • the resulting formulation contains the following ingredients by weight percent: 95% petrolatum, 0.2% Itraconazole, 0.13% BZK, and 4.67% water.
  • the formulation is observed to be stable for at least 6 months. During the 6 month observation period, the anti-fungal solution remains substantially suspended in the petrolatum carrier thereby resulting in a composition suitable for therapeutic use for the treatment of onychomycosis by topical administration to the nail and surrounding skin of a subject in need thereof.
  • Formulation 10 is prepared in accordance with the present disclosure by mixing Itraconazole and water to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to a temperature from about 1°C to about 5°C higher than the temperature of the melted petrolatum and mixed.
  • a stable petrolatum-based Itraconazole composition is formed, which comprises from about 0.01% to about 5% by weight Itraconazole and greater than 85% petrolatum.
  • one or more cationic biocides is added to the anti-fungal agent solution prior to mixing with the melted petrolatum such that the resultant stable petrolatum-based composition further includes from about 0.001% to about 0.15% cationic biocide.
  • Such cationic biocides may include, for example, benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • Example 15 Topical Administration of Petrolatum-Based Compositions Comprising Itraconazole Improves Clinical Outcomes in Subjects Having Onychomycosis
  • Formulations 9 and 10 petrolatum- based compositions comprising Itraconazole
  • topical administration of Formulations 9 and 10 in the treatment of human subjects having onychomycosis will be studied using a randomized, double-blind clinical study.
  • a group of human subjects will be topically administered the compositions corresponding to Formulations 9 and 10 of Examples 13 and 14.
  • the petrolatum- based compositions comprising Itraconazole will be applied to the nail of a subject having or otherwise affected by onychomycosis. Subjects receiving such treatment will have improved standard clinical outcomes.
  • subjects receiving treatment according to the presently disclosed methods and techniques are will exhibit a reduced rate of occurrence of onychomycosis in the nails or portions thereof receiving treatment as well as reduced clinical signs of onychomycosis.
  • Similar improved standard clinical outcomes will be obtained for subjects having onychomycosis caused by T. rubrum, Candida, as well as for the distal subungual onychomycosis, white superficial onychomycosis (WSO), proximal subungual onychomycosis, and Candidal onychomycosis sub-types of onychomycosis.
  • Example 16 Exemplary Formulation Process: Petrolatum-Based Ketoconazole Composition
  • Formulation 11 is prepared by adding 2540.3 pounds of white petrolatum to a tank that has been cleaned and sterilized.
  • the petrolatum in the tanks is heated to 110°C to 113°F in order to cause the petrolatum to melt.
  • 133.70 pounds of water is mixed with Ketoconazole and BZK to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to 122°F. With the melted petrolatum at a temperature from about 110°F to about 113°F and the anti-fungal agent solution at a temperature of 122°F, the anti-fungal agent solution is slowly added to the petrolatum while mixing.
  • the heat is decreased slowly to from about 96°F to about 104°F.
  • the resulting formulation contains the following ingredients by weight percent: 95% petrolatum, 0.2% Ketoconazole, 0.13% BZK, and 4.67% water.
  • the formulation is observed to be stable for at least 6 months. During the 6 month observation period, the anti-fungal solution remains substantially suspended in the petrolatum carrier thereby resulting in a composition suitable for therapeutic use for the treatment of onychomycosis by topical administration to the nail and surrounding skin of a subject in need thereof.
  • Formulation 12 is prepared in accordance with the present disclosure by mixing Ketoconazole and water to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to a temperature from about 1°C to about 5°C higher than the temperature of the melted petrolatum and mixed.
  • a stable petrolatum-based Ketoconazole composition is formed, which comprises from about 0.01% to about 5% by weight Ketoconazole and greater than 85% petrolatum.
  • one or more cationic biocides is added to the anti-fungal agent solution prior to mixing with the melted petrolatum such that the resultant stable petrolatum-based composition further includes from about 0.001% to about 0.15% cationic biocide.
  • Such cationic biocides may include, for example, benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • Example 18 Topical Administration of Petrolatum-Based Compositions Comprising Ketoconazole Improves Clinical Outcomes in Subjects Having Onychomycosis
  • Formulation 13 is prepared by adding 2540.3 pounds of white petrolatum to a tank that has been cleaned and sterilized.
  • the petrolatum in the tanks is heated to 110°C to 113°F in order to cause the petrolatum to melt.
  • 133.70 pounds of water is mixed with Amorolfine and BZK to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to 122°F. With the melted petrolatum at a temperature from about 110°F to about 113°F and the anti-fungal agent solution at a temperature of 122°F, the anti-fungal agent solution is slowly added to the petrolatum while mixing.
  • the heat is decreased slowly to from about 96°F to about 104°F.
  • the resulting formulation contains the following ingredients by weight percent: 95% petrolatum, 0.2% Amorolfine, 0.13% BZK, and 4.67% water.
  • the formulation is observed to be stable for at least 6 months. During the 6 month observation period, the anti-fungal solution remains substantially suspended in the petrolatum carrier thereby resulting in a composition suitable for therapeutic use for the treatment of onychomycosis by topical administration to the nail and surrounding skin of a subject in need thereof.
  • Formulation 14 is prepared in accordance with the present disclosure by mixing Amorolfine and water to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to a temperature from about 1°C to about 5°C higher than the temperature of the melted petrolatum and mixed.
  • a stable petrolatum-based Amorolfine composition is formed, which comprises from about 0.01% to about 5% by weight Amorolfine and greater than 85% petrolatum.
  • one or more cationic biocides is added to the anti-fungal agent solution prior to mixing with the melted petrolatum such that the resultant stable petrolatum-based composition further includes from about 0.001% to about 0.15% cationic biocide.
  • Such cationic biocides may include, for example, benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • Example 22 Exemplary Formulation Process: Petrolatum-Based Efinaconazole Composition
  • Formulation 15 is prepared by adding 2540.3 pounds of white petrolatum to a tank that has been cleaned and sterilized.
  • the petrolatum in the tanks is heated to 110°C to 113°F in order to cause the petrolatum to melt.
  • 133.70 pounds of water is mixed with Efinaconazole and BZK to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to 122°F. With the melted petrolatum at a temperature from about 110°F to about 113°F and the anti-fungal agent solution at a temperature of 122°F, the anti-fungal agent solution is slowly added to the petrolatum while mixing.
  • the heat is decreased slowly to from about 96°F to about 104°F.
  • the resulting formulation contains the following ingredients by weight percent: 95% petrolatum, 0.2% Efinaconazole, 0.13% BZK, and 4.67% water.
  • the formulation is observed to be stable for at least 6 months. During the 6 month observation period, the anti-fungal solution remains substantially suspended in the petrolatum carrier thereby resulting in a composition suitable for therapeutic use for the treatment of onychomycosis by topical administration to the nail and surrounding skin of a subject in need thereof.
  • Formulation 16 is prepared in accordance with the present disclosure by mixing Efinaconazole and water to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to a temperature from about 1°C to about 5°C higher than the temperature of the melted petrolatum and mixed.
  • a stable petrolatum-based Efinaconazole composition is formed, which comprises from about 0.01% to about 5% by weight Efinaconazole and greater than 85% petrolatum.
  • one or more cationic biocides is added to the anti-fungal agent solution prior to mixing with the melted petrolatum such that the resultant stable petrolatum-based composition further includes from about 0.001% to about 0.15% cationic biocide.
  • cationic biocides may include, for example, benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • Example 24 Topical Administration of Petrolatum-Based Compositions Comprising Efinaconazole Improves Clinical Outcomes in Subjects Having Onychomycosis
  • compositions comprising Efinaconazole in the treatment of human subjects having onychomycosis will be studied using a randomized, double-blind clinical study.
  • a group of human subjects will be topically administered the compositions corresponding to Formulations 15 and 16 of Examples 22 and 23.
  • the petrolatum- based compositions comprising Efinaconazole will be applied to the nail of a subject having or otherwise affected by onychomycosis. Subjects receiving such treatment will have improved standard clinical outcomes.
  • subjects receiving treatment according to the presently disclosed methods and techniques are will exhibit a reduced rate of occurrence of onychomycosis in the nails or portions thereof receiving treatment as well as reduced clinical signs of onychomycosis.
  • Similar improved standard clinical outcomes will be obtained for subjects having onychomycosis caused by T. rubrum, Candida, as well as for the distal subungual onychomycosis, white superficial onychomycosis (WSO), proximal subungual onychomycosis, and Candidal onychomycosis sub-types of onychomycosis.
  • Example 25 Exemplary Formulation Process: Petrolatum-Based Clotrimazole Composition
  • Formulation 17 is prepared by adding 2540.3 pounds of white petrolatum to a tank that has been cleaned and sterilized.
  • the petrolatum in the tanks is heated to 110°C to 113°F in order to cause the petrolatum to melt.
  • 133.70 pounds of water is mixed with Clotrimazole and BZK to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to 122°F. With the melted petrolatum at a temperature from about 110°F to about 113°F and the anti-fungal agent solution at a temperature of 122°F, the anti-fungal agent solution is slowly added to the petrolatum while mixing.
  • the heat is decreased slowly to from about 96°F to about 104°F.
  • the resulting formulation contains the following ingredients by weight percent: 95% petrolatum, 0.2% Clotrimazole, 0.13% BZK, and 4.67% water.
  • the formulation is observed to be stable for at least 6 months. During the 6 month observation period, the anti-fungal solution remains substantially suspended in the petrolatum carrier thereby resulting in a composition suitable for therapeutic use for the treatment of onychomycosis by topical administration to the nail and surrounding skin of a subject in need thereof.
  • Example 26 Petrolatum-Based Compositions Comprising Clotrimazole
  • Formulation 18 is prepared in accordance with the present disclosure by mixing Clotrimazole and water to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to a temperature from about 1°C to about 5°C higher than the temperature of the melted petrolatum and mixed.
  • a stable petrolatum-based Clotrimazole composition is formed, which comprises from about 0.01% to about 5% by weight Clotrimazole and greater than 85% petrolatum.
  • one or more cationic biocides is added to the anti-fungal agent solution prior to mixing with the melted petrolatum such that the resultant stable petrolatum-based composition further includes from about 0.001% to about 0.15% cationic biocide.
  • Such cationic biocides may include, for example, benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • Example 27 Topical Administration of Petrolatum-Based Compositions Comprising Clotrimazole Improves Clinical Outcomes in Subjects Having Onychomycosis
  • compositions comprising Clotrimazole in the treatment of human subjects having onychomycosis will be studied using a randomized, double-blind clinical study.
  • a group of human subjects will be topically administered the compositions corresponding to Formulations 17 and 18 of Examples 25 and 26.
  • the petrolatum- based compositions comprising Clotrimazole will be applied to the nail of a subject having or otherwise affected by onychomycosis.
  • Subjects receiving such treatment will have improved standard clinical outcomes.
  • subjects receiving treatment according to the presently disclosed methods and techniques are will exhibit a reduced rate of occurrence of onychomycosis in the nails or portions thereof receiving treatment as well as reduced clinical signs of onychomycosis.
  • Example 28 Exemplary Formulation Process: Petrolatum-Based Miconazole (Miconazole Nitrate) Composition
  • Formulation 19 is prepared by adding 2540.3 pounds of white petrolatum to a tank that has been cleaned and sterilized.
  • the petrolatum in the tanks is heated to 110°C to 113°F in order to cause the petrolatum to melt.
  • 133.70 pounds of water is mixed with Miconazole (Miconazole Nitrate) and BZK to form an anti-fungal agent solution.
  • the anti-fungal agent solution is heated to 122°F. With the melted petrolatum at a temperature from about 110°F to about 113°F and the anti-fungal agent solution at a temperature of 122°F, the anti-fungal agent solution is slowly added to the petrolatum while mixing.
  • the heat is decreased slowly to from about 96°F to about 104°F.
  • the resulting formulation contains the following ingredients by weight percent: 95% petrolatum, 0.2% Miconazole (Miconazole Nitrate), 0.13% BZK, and 4.67% water.
  • the formulation is observed to be stable for at least 6 months. During the 6 month observation period, the anti-fungal solution remains substantially suspended in the petrolatum carrier thereby resulting in a composition suitable for therapeutic use for the treatment of onychomycosis by topical administration to the nail and surrounding skin of a subject in need thereof.
  • Example 29 Petrolatum-Based Compositions Comprising Miconazole (Miconazole Nitrate)
  • Formulation 20 is prepared in accordance with the present disclosure by mixing Miconazole (Miconazole Nitrate) and water to form an anti-fungal agent solution.
  • the anti- fungal agent solution is heated to a temperature from about 1°C to about 5°C higher than the temperature of the melted petrolatum and mixed.
  • a stable petrolatum-based Miconazole (Miconazole Nitrate) composition is formed, which comprises from about 0.01% to about 5% by weight Miconazole (Miconazole Nitrate) and greater than 85% petrolatum.
  • one or more cationic biocides is added to the anti-fungal agent solution prior to mixing with the melted petrolatum such that the resultant stable petrolatum-based composition further includes from about 0.001% to about 0.15% cationic biocide.
  • cationic biocides may include, for example, benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • Example 30 Topical Administration of Petrolatum-Based Compositions Comprising Miconazole (Miconazole Nitrate) Improves Clinical Outcomes in Subjects Having Onychomycosis
  • subjects receiving treatment according to the presently disclosed methods and techniques are will exhibit a reduced rate of occurrence of onychomycosis in the nails or portions thereof receiving treatment as well as reduced clinical signs of onychomycosis.
  • Similar improved standard clinical outcomes will be obtained for subjects having onychomycosis caused by T. rubrum, Candida, as well as for the distal subungual onychomycosis, white superficial onychomycosis (WSO), proximal subungual onychomycosis, and Candidal onychomycosis sub-types of onychomycosis.
  • Statement 1 A method of treating onychomycosis in a subject, the method comprising applying a petrolatum-based composition to the nail of a subject in need of treatment, wherein the petrolatum-based composition comprises one or more anti-fungal agents and a petrolatum carrier.
  • Statement 2 The method according to Statement 2, wherein the one or more anti-fungal agents is dispersed in the petrolatum carrier to form a stable petrolatum-based suspension.
  • Statement 3 The method according to Statement 1 or Statement 2, wherein the one or more anti-fungal agents is dispersed in the petrolatum carrier in the form of nanodroplets.
  • Statement 4 The method according to any one of Statements 1-3, wherein the petrolatum-based composition comprises nanodroplets dispersed in the petrolatum carrier, wherein the nanodroplets comprises one or more fungal agents and a polar solvent.
  • Statement 5 The method according to any one of Statements 1-4, wherein the one or more anti-fungal agents is dissolved in a polar solvent to form an anti-fungal agent solution, the anti-fungal agent solution dispersed in the petrolatum to form a stable suspension.
  • Statement 6 The method according to Statement 5, wherein the anti fungal agent solution is dispersed in the petrolatum in the form of nanodroplets.
  • Statement 7 The method according to any one of Statements 1-6, wherein the one or more anti-fungal agents is selected from the group consisting of terbinafine HC1, ciclopirox, ciclopirox olamine, fluconazole, itraconazole, ketoconazole, amorolfine, efinaconazole, clotrimazole, miconazole (miconazole nitrate), and any combination thereof.
  • the one or more anti-fungal agents is selected from the group consisting of terbinafine HC1, ciclopirox, ciclopirox olamine, fluconazole, itraconazole, ketoconazole, amorolfine, efinaconazole, clotrimazole, miconazole (miconazole nitrate), and any combination thereof.
  • Statement 8 The method according to any one of Statements 1-7, wherein the onychomycosis is caused by Trichophyton rubrum (T. rubrum).
  • Statement 9 The method according to any one of Statements 1-7, wherein the onychomycosis is caused by Candida.
  • Statement 10 The method according to any one of Statements 1-7, wherein the onychomycosis is distal subungual onychomycosis.
  • Statement 11 The method according to any one of Statements 1-7, wherein the onychomycosis is white superficial onychomycosis (WSO).
  • WSO white superficial onychomycosis
  • Statement 12 The method according to any one of Statements 1-7, wherein the onychomycosis is proximal subungual onychomycosis.
  • Statement 13 The method according to any one of Statements 1-7, wherein the onychomycosis is Candidal onychomycosis.
  • Statement 14 The method according to Statement 13, wherein the
  • Candidal onychomycosis is caused by Candida auris (C. auris).
  • Statement 15 The method according to Statement 14, wherein the C. auris is multi-drug resistant C. auris.
  • Statement 16 The method according to any one of Statements 1-15, wherein the one or more anti-fungal agents comprises from about 0.05% to about 5% by weight of the petrolatum-based composition.
  • Statement 17 The method according to any one of Statements 1-15, wherein the one or more anti-fungal agents comprises from about 0.05% to about 3% by weight of the petrolatum-based composition.
  • Statement 18 The method according to any one of Statements 1-15, wherein the one or more anti- fungal agents comprises from about 0.1% to about 1% by weight of the petrolatum-based composition.
  • Statement 19 The method according to any one of Statements 1-15, wherein the one or more anti-fungal agents comprises from about 0.2% to about 0.6% by weight of the petrolatum-based composition.
  • Statement 20 The method according to any one of Statements 1-15, wherein the one or more anti-fungal agents comprises from about 0.3% to about 0.5% by weight of the petrolatum-based composition.
  • Statement 21 The method according to any one of Statements 1-15, wherein the one or more anti-fungal agents comprises from about 0.1% to about 3.5% by weight of the petrolatum-based composition.
  • Statement 22 The method according to any one of Statements 1-15, wherein the one or more anti-fungal agents comprises from about 0.05% to about 2.5% by weight of the petrolatum-based composition.
  • Statement 23 The method according to any one of Statements 1-15, wherein the one or more anti-fungal agents comprises from about 0.5% to about 3% by weight of the petrolatum-based composition.
  • Statement 24 The method according to any one of Statements 1-15, wherein the one or more anti-fungal agents comprises from about 0.5% to about 2.5% by weight of the petrolatum-based composition.
  • Statement 25 The method according to any one of Statements 1-15, wherein the one or more anti-fungal agents comprises from about 1.5% to about 2.5% by weight of the petrolatum-based composition.
  • Statement 26 The method according to any one of Statements 1-25, wherein the petrolatum-based composition comprises greater than about 80% by weight petrolatum.
  • Statement 27 The method according to any one of Statements 1-25, wherein the petrolatum-based composition comprises greater than about 90% by weight petrolatum.
  • Statement 28 The method according to any one of Statements 1-25, wherein the petrolatum-based composition comprises greater than about 95% by weight petrolatum.
  • Statement 29 The method according to any one of Statements 1-28, wherein the petrolatum-based composition contains no emulsifier.
  • Statement 30 The method according to any one of Statements 1-28, wherein the petrolatum-based composition excludes an added emulsifier.
  • Statement 31 The method according to any one of Statements 1-30, wherein the petrolatum-based composition further includes a cationic biocide selected from the group consisting of benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • Statement 32 The method according to Statement 31, wherein the petrolatum-based composition comprises from about 0.001% to about 0.15% by weight benzalkonium chloride (BZK).
  • BZK benzalkonium chloride
  • Statement 33 The method according to Statement 31, wherein the petrolatum-based composition comprises from about 0.001% to about 0.01% or from about 0.005% to about 0.007% by weight benzalkonium chloride (BZK).
  • BZK benzalkonium chloride
  • Statement 34 The method according to any one of Statements 1-33, wherein the petrolatum-based composition is prepared by a process comprising: a) dissolving the one or more anti-fungal agents in a polar solvent to give an anti-fungal agent solution; b) heating the petrolatum to a temperature sufficient to cause the petrolatum to melt to give a melted petrolatum and heating the anti-fungal agent solution to a temperature higher than the temperature of the melted petrolatum to give a heated anti-fungal agent solution; c) mixing the melted petrolatum and the heated anti-fungal agent solution to give a melted mixture; and d) cooling the melted mixture to give the petrolatum-based composition.
  • Statement 35 The method according to Statement 34, wherein the heated anti- fungal agent solution has a temperature that is about 1°C to about 5°C higher than the temperature of the melted petrolatum.
  • Statement 36 The method according to any one of Statements 1-35, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight terbinafine HC1.
  • Statement 37 The method according to any one of Statements 1-35, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight ciclopirox.
  • Statement 38 The method according to any one of Statements 1-35, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight ciclopirox olamine.
  • Statement 39 The method according to any one of Statements 1-35, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight fluconazole.
  • Statement 40 The method according to any one of Statements 1-35, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight itraconazole.
  • Statement 41 The method according to any one of Statements 1-35, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight ketoconazole.
  • Statement 42 The method according to any one of Statements 1-35, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight amorolfine.
  • Statement 43 The method according to any one of Statements 1-35, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight efinaconazole.
  • Statement 44 A petrolatum-based composition for the treatment of onychomycosis, the composition comprising a pharmaceutically effective amount of one or more anti- fungal agents in a petrolatum carrier.
  • Statement 45 The composition according to Statement 44, wherein the one or more anti- fungal agents is dispersed in the petrolatum carrier to form a stable petrolatum- based suspension.
  • Statement 46 The composition according to Statement 44 or Statement 45, wherein the one or more anti-fungal agents is dispersed in the petrolatum carrier in the form of nanodroplets.
  • Statement 47 The composition according to any one of Statements 44-46, wherein the petrolatum-based composition comprises nanodroplets dispersed in the petrolatum carrier, wherein the nanodroplets comprises one or more fungal agents and a polar solvent.
  • Statement 48 The composition according to any one of Statements 44-47, wherein the one or more anti-fungal agents is dissolved in a polar solvent to form an anti-fungal agent solution, the anti-fungal agent solution dispersed in the petrolatum to form a stable suspension.
  • Statement 49 The composition according to Statement 48, wherein the anti-fungal agent solution is dispersed in the petrolatum in the form of nanodroplets.
  • Statement 50 The composition according to any one of Statements 44-49, wherein the one or more anti-fungal agents is selected from the group consisting of terbinafine HC1, ciclopirox, ciclopirox olamine, fluconazole, itraconazole, ketoconazole, amorolfine, efinaconazole, clotrimazole, miconazole (miconazole nitrate), and any combination thereof.
  • the one or more anti-fungal agents is selected from the group consisting of terbinafine HC1, ciclopirox, ciclopirox olamine, fluconazole, itraconazole, ketoconazole, amorolfine, efinaconazole, clotrimazole, miconazole (miconazole nitrate), and any combination thereof.
  • Statement 51 The composition according to any one of Statements 44-50, wherein the onychomycosis is caused by Trichophyton rubrum (T. rubrum).
  • Statement 52 The composition according to any one of Statements 44-50, wherein the onychomycosis is caused by Candida.
  • Statement 53 The composition according to any one of Statements 44-50, wherein the onychomycosis is distal subungual onychomycosis.
  • Statement 54 The composition according to any one of Statements 44-50, wherein the onychomycosis is white superficial onychomycosis (WSO).
  • WSO white superficial onychomycosis
  • Statement 55 The composition according to any one of Statements 44-50, wherein the onychomycosis is proximal subungual onychomycosis.
  • Statement 56 The composition according to any one of Statements 44-50, wherein the onychomycosis is Candidal onychomycosis.
  • Statement 57 The composition according to Statement 56, wherein the Candidal onychomycosis is caused by Candida auris (C. auris).
  • Statement 58 The composition according to Statement 57, wherein the C. auris is multi-drug resistant C. auris.
  • Statement 59 The composition according to any one of Statements 44-58, wherein the one or more anti-fungal agents comprises from about 0.05% to about 5% by weight of the petrolatum-based composition.
  • Statement 60 The composition according to any one of Statements 44-58, wherein the one or more anti-fungal agents comprises from about 0.05% to about 3% by weight of the petrolatum-based composition.
  • Statement 61 The composition according to any one of Statements 44-58, wherein the one or more anti- fungal agents comprises from about 0.1% to about 1% by weight of the petrolatum-based composition.
  • Statement 62 The composition according to any one of Statements 44-58, wherein the one or more anti-fungal agents comprises from about 0.2% to about 0.6% by weight of the petrolatum-based composition.
  • Statement 63 The composition according to any one of Statements 44-58, wherein the one or more anti-fungal agents comprises from about 0.3% to about 0.5% by weight of the petrolatum-based composition.
  • Statement 64 The composition according to any one of Statements 44-58, wherein the one or more anti-fungal agents comprises from about 0.1% to about 3.5% by weight of the petrolatum-based composition.
  • Statement 65 The composition according to any one of Statements 44-58, wherein the one or more anti-fungal agents comprises from about 0.05% to about 2.5% by weight of the petrolatum-based composition.
  • Statement 66 The composition according to any one of Statements 44-58, wherein the one or more anti-fungal agents comprises from about 0.5% to about 3% by weight of the petrolatum-based composition.
  • Statement 67 The composition according to any one of Statements 44-58, wherein the one or more anti-fungal agents comprises from about 0.5% to about 2.5% by weight of the petrolatum-based composition.
  • Statement 68 The composition according to any one of Statements 44-58, wherein the one or more anti-fungal agents comprises from about 1.5% to about 2.5% by weight of the petrolatum-based composition.
  • Statement 69 The composition according to any one of Statements 44-68, wherein the petrolatum-based composition comprises greater than about 80% by weight petrolatum.
  • Statement 70 The composition according to any one of Statements 44-68, wherein the petrolatum-based composition comprises greater than about 90% by weight petrolatum.
  • Statement 71 The composition according to any one of Statements 44-68, wherein the petrolatum-based composition comprises greater than about 95% by weight petrolatum.
  • Statement 72 The composition according to any one of Statements 44-71, wherein the petrolatum-based composition contains no emulsifier.
  • Statement 73 The composition according to any one of Statements 44-71, wherein the petrolatum-based composition excludes an added emulsifier.
  • Statement 74 The composition according to any one of Statements 44-73, wherein the petrolatum-based composition further includes a cationic biocide selected from the group consisting of benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • a cationic biocide selected from the group consisting of benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.
  • Statement 75 The composition according to Statement 74, wherein the petrolatum-based composition comprises from about 0.001% to about 0.15% by weight benzalkonium chloride (BZK).
  • BZK benzalkonium chloride
  • Statement 76 The composition according to Statement 74, wherein the petrolatum-based composition comprises from about 0.001% to about 0.01% or from about 0.005% to about 0.007% by weight benzalkonium chloride (BZK).
  • BZK benzalkonium chloride
  • Statement 77 The composition according to any one of Statements 44-76, wherein the petrolatum-based composition is prepared by a process comprising: a) dissolving the one or more anti-fungal agents in a polar solvent to give an anti-fungal agent solution; b) heating the petrolatum to a temperature sufficient to cause the petrolatum to melt to give a melted petrolatum and heating the anti-fungal agent solution to a temperature higher than the temperature of the melted petrolatum to give a heated anti-fungal agent solution; c) mixing the melted petrolatum and the heated anti-fungal agent solution to give a melted mixture; and d) cooling the melted mixture to give the petrolatum-based composition.
  • Statement 78 The composition according to Statement 77, wherein the heated anti- fungal agent solution has a temperature that is about 1°C to about 5°C higher than the temperature of the melted petrolatum.
  • Statement 79 The composition according to any one of Statements 44-78, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight terbinafine HC1.
  • Statement 80 The composition according to any one of Statements 44-78, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight ciclopirox.
  • Statement 81 The composition according to any one of Statements 44-78, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight ciclopirox olamine.
  • Statement 82 The composition according to any one of Statements 44-78, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight fluconazole.
  • Statement 83 The composition according to any one of Statements 44-78, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight itraconazole.
  • Statement 84 The composition according to any one of Statements 44-78, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight ketoconazole.
  • Statement 85 The composition according to any one of Statements 44-78, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight amorolfine.
  • Statement 86 The composition according to any one of Statements 44-78, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight efinaconazole.
  • Statement 87 The composition according to any one of Statements 44-78, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight clotrimazole.
  • Statement 88 The composition according to any one of Statements 44-78, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight miconazole (miconazole nitrate).
  • Statement 89 The method according to any one of Statements 1-35, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight clotrimazole.
  • Statement 90 The method according to any one of Statements 1-35, wherein the petrolatum-based composition comprises from about 0.01% to about 5% by weight miconazole (miconazole nitrate).

Abstract

La présente invention concerne des compositions et des méthodes de traitement de l'onychomycose. Les compositions comprennent une quantité pharmaceutiquement efficace d'un ou de plusieurs agents antifongiques dans un excipient à base de pétrolatum. Le ou les agents antifongiques peuvent comprendre, par exemple, du chlorhydrate de terbinafine, du ciclopirox, de la ciclopirox olamine, du fluconazole, de l'itraconazole, du kétoconazole, de l'amorolfine, de l'éfinaconazole, du clotrimazole, du miconazole (nitrate de miconazole), et une combinaison quelconque de ceux-ci.
PCT/US2020/013959 2019-01-16 2020-01-16 Compositions à base de pétrolatum et méthodes de traitement de l'onychomycose WO2020150531A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021541460A JP2022522991A (ja) 2019-01-16 2020-01-16 爪甲真菌症のためのワセリンベース組成物及び治療方法
EP20741114.1A EP3911337A4 (fr) 2019-01-16 2020-01-16 Compositions à base de pétrolatum et méthodes de traitement de l'onychomycose
CA3127052A CA3127052A1 (fr) 2019-01-16 2020-01-16 Compositions a base de petrolatum et methodes de traitement de l'onychomycose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962793317P 2019-01-16 2019-01-16
US62/793,317 2019-01-16

Publications (1)

Publication Number Publication Date
WO2020150531A1 true WO2020150531A1 (fr) 2020-07-23

Family

ID=71613212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/013959 WO2020150531A1 (fr) 2019-01-16 2020-01-16 Compositions à base de pétrolatum et méthodes de traitement de l'onychomycose

Country Status (4)

Country Link
EP (1) EP3911337A4 (fr)
JP (1) JP2022522991A (fr)
CA (1) CA3127052A1 (fr)
WO (1) WO2020150531A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479532B1 (en) * 1999-04-16 2002-11-12 Fujisawa Pharmaceutical Co., Ltd. Antifungal compositions
US20050186161A1 (en) * 2002-08-23 2005-08-25 Ssp Co., Ltd. Antifungal and/or antimycotic external preparation for nail
US20120010246A1 (en) * 2010-07-08 2012-01-12 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US20130261131A1 (en) * 2012-03-30 2013-10-03 Nian Wu Pharmaceutical compositions and mentods for treatment of fungal infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160271121A1 (en) * 2015-03-16 2016-09-22 Gavis Pharmaceuticals Antifungal combination therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479532B1 (en) * 1999-04-16 2002-11-12 Fujisawa Pharmaceutical Co., Ltd. Antifungal compositions
US20050186161A1 (en) * 2002-08-23 2005-08-25 Ssp Co., Ltd. Antifungal and/or antimycotic external preparation for nail
US20120010246A1 (en) * 2010-07-08 2012-01-12 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US20130261131A1 (en) * 2012-03-30 2013-10-03 Nian Wu Pharmaceutical compositions and mentods for treatment of fungal infections

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LASSUS A. ET AL.: "Comparison of ciclopirox olamine 1% cream with ciclopirox 1 %-hydrocortisone acetate 1% cream in the treatment of inflamed superficial mycoses", CLINICAL THERAPEUTICS, vol. 10, no. 5, December 1987 (1987-12-01), pages 594 - 599, XP009098493 *
PREPARATION OF OINTMENT BASES, 17 August 2017 (2017-08-17), XP055726592, Retrieved from the Internet <URL:https://web.archive.org/web/20170513162658/http://pharmlabs.unc.edu/labs/ointments/prep.htm> *
See also references of EP3911337A4 *

Also Published As

Publication number Publication date
CA3127052A1 (fr) 2020-07-23
JP2022522991A (ja) 2022-04-21
EP3911337A4 (fr) 2022-10-26
EP3911337A1 (fr) 2021-11-24

Similar Documents

Publication Publication Date Title
DE60032021T2 (de) Verabreichung eines arzneistoffs mittels einer sich phasenumwandelnden formulierung
KR101453601B1 (ko) 주입으로 인한 피부 반응 감소를 위한 필러와 아드레날린 수용체 작용제의 주사가능한 조합
CA2391310C (fr) Methode et composition pour le traitement de cicatrices
KR101792200B1 (ko) 열감응성 겔 마취제 조성물
DE10337340B4 (de) Zusammensetzung
DE602004010248T2 (de) Externes pflaster mit östrogen und/oder gestagen
DE69829510T2 (de) Stabile Zubereitung enthaltend Acetylsalicylsäure und Siliconöl zur äusseren Anwendung
US7273887B1 (en) Topical anesthetic formulation
US20040131665A1 (en) Topical anesthetic formulation
US20110319805A1 (en) Topical composition for treating the skin
US11116734B2 (en) Petrolatum-based compositions and methods of treatment for onychomycosis
US20210401779A1 (en) Petrolatum-based compositions and methods of treatment for onychomycosis
EP3911337A1 (fr) Compositions à base de pétrolatum et méthodes de traitement de l&#39;onychomycose
JP2019515882A (ja) 貯蔵安定性の眼用組成物
CN113347982A (zh) 真皮皮肤保护剂和载体
BR112021014073A2 (pt) Composições à base de petrolato e métodos de tratamento para onicomicose
EP3911306B1 (fr) Compositions de phmb à base de pétrolatum et méthodes de traitement de l&#39;onychomycose
AU2003234758B2 (en) Composition
WO2021257027A1 (fr) Composition efficace pour la cicatrisation de plaies
US11110071B2 (en) Petrolatum-based PHMB compositions and methods of treatment for onychomycosis
JP2002507563A (ja) 神経腫の疼痛を処置する方法
RU2349302C1 (ru) Фармацевтическая композиция для наружного применения &#34;офломелид&#34; при гнойно-воспалительных заболеваниях
WO2021051028A1 (fr) Compositions et procédés de soin de plaies à base d&#39;huile
WO2020069222A1 (fr) Compositions de neurotoxines topiques
WO2020069225A1 (fr) Compositions phmb et méthodes de traitement du cancer de la peau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20741114

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021541460

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3127052

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021014073

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020741114

Country of ref document: EP

Effective date: 20210816

ENP Entry into the national phase

Ref document number: 112021014073

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210716